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Abstract 
Nanotechnology-based antitumor drug delivery systems, known as nanocarriers, have 
demonstrated their efficacy in recent years. Typically, the size of the nanocarriers is around 100 nm. 
It is imperative to achieve an optimum size of these nanocarriers which must be designed uniquely 
for each type of delivery process. For pH-responsive nanocarriers with programmable size, changes 
in pH (~6.5 for tumor tissue, ~5.5 for endosomes, and ~5.0 for lysosomes) may serve as an 
endogenous stimulus improving the safety and therapeutic efficacy of antitumor drugs. This review 
focuses on current advanced pH-responsive nanocarriers with programmable size changes for 
anticancer drug delivery. In particular, pH-responsive mechanisms for nanocarrier retention at 
tumor sites, size reduction for penetrating into tumor parenchyma, escaping from endo/lysosomes, 
and swelling or disassembly for drug release will be highlighted. Additional trends and challenges of 
employing these nanocarriers in future clinical applications are also addressed. 
Key words: nanocarriers, endogenous pH-responsive, size change, targeted drug delivery, tumor therapy 
1. Introduction 
Over the last decade, tremendous progress has 
been made in the development of nanocarriers as 
effective antitumor drug delivery agents. These 
carriers are highly attractive due to their nanometer 
size and versatile surface properties, which enhance 
their pharmacokinetics and bio-distribution while 
reducing systemic toxicity [1-5]. To date, a broad 
range of nanocarriers has been designed and tested, 
including polymer nanoparticles, micelles, liposomes, 
dendrimers, star polymers, and inorganic 
nanoparticles made of iron oxide, quantum dots, 
silica, gold, and metal oxide frameworks [1, 6-18]. 
Intravenously injected nanomedicine undergoes a 
multistep process before reaching solid tumors [19, 
20]. Therefore, for efficient drug delivery in the 
complex in vivo environment, it is important to 
develop multiple stimuli-responsive nanocarriers that 
can minimize nonspecific interactions with and 
uptake by non-targeted cells or the immune system [6, 
21-24]. Specifically designed intelligent 
stimuli-sensitive nanocarriers can increase the 
concentration of effective anticancer drugs by 
targeting their delivery to tumor locations, thus 
allowing for greater therapeutic efficacy and reducing 
undesired side effects. 
Although much work has been carried out on the 
development of drug-delivery systems affected by 









hindered their biomedical application. For example, 
several temperature- and light-sensitive 
pharmaceuticals can damage normal cells and even 
tissues and organs. The magnetic-associated 
preparations (used as contrast agents in MRI) are 
limited by the stringent requirements of carrier 
materials. The ultrasound-associated formulations are 
usually used for synergistic therapy. Considering the 
limitations of external stimulant sources (e.g. light, 
ultrasound, magnetic fields), endogenous 
stimulations, such as enzymes [25-29], glucose 
concentrations [30, 31], redox reactions [32-38], 
temperatures [39-41] and pH differences [34, 42-51], 
are more useful when designing safe, efficient, and 
intelligent carriers. Among these endogenous stimuli, 
pH differences have been the most widely used 
control parameter for tumor-targeted drug delivery 
and controlled intracellular drug release. This is 
possible due to the pH differences between healthy 
and diseased tissues as well as between various 
cellular compartments [6, 52-56]. Given the 
vulnerability of acid-base homeostasis, acidic 
microenvironment changes are associated with 
pathological tissues, such as in ischemia, 
inflammatory diseases, infections, rheumatoid 
arthritis, or solid tumors [6, 52, 57-60]. Especially in 
solid tumor tissues, the substantial energy 
requirement for their intensive growth results in 
increased lactate and hydrogen ions (H+) produced by 
catabolism of glucose. Consequently, the tumor 
microenvironment becomes acidic with a pH ~6.5 in 
tumor tissues versus pH ~7.4 in normal tissues [57, 
61-63]. This difference can then be exploited for 
targeting the tumor tissue or triggering drug release 
in the tumor’s extracellular matrix [60, 64-68]. At the 
cellular level, the intracellular acidic components (pH 
~5.5 for endosome, pH ~5.0 for lysosome) can also be 
used to trigger drug release and promote the escape of 
the carrier into the cytoplasm [6, 69-72]. Therefore, 
these endogenous pH differences provide a strong 
option for targeted antitumor drug delivery and 
controllable release kinetics. 
In general, the physicochemical characteristics of 
nanocarriers, including size, architecture, and surface 
properties determine their fate by affecting one or 
more of the above steps in the antitumor drug 
delivery process [1, 47, 49, 52, 60, 64, 73-75]. 
Size-dependent enhanced antitumor findings have 
received much attention because of the variable and 
strict size requirements of the entire cascade 
processes, including their biodistribution, immune 
activation, blood circulation, tumor target 
accumulation/retention, tumor tissue penetration, 
tumor cell uptake, and final cargo release (Figure 1) 
[52, 76-81]. For example, small nanocarriers (typically 
<10-20 nm) can spread into various organs, but they 
are also rapidly eliminated through the kidneys’ 
glomeruli [1, 82]. Large nanocarriers (typically >200 
nm) tend to be rapidly taken up by the mononuclear 
phagocytic system (MPS) and subsequently 
accumulate in the liver, spleen, and to a lesser extent 
in the bone marrow [1, 83-88]. Compared to the tight 
endothelial junctions of normal vessels (5-10 nm), the 
pores of tumor vascular walls have typical junction 
sizes ranging from 200 nm to 1200 nm allowing 
extravasation of appropriately sized nanocarriers into 
solid tumors [1, 19]. Also, the lack of functional 
lymphatic drainage in tumor tissues prevented the 
reentry of accumulated nanocarriers into blood 
circulation. This phenomenon, termed the enhanced 
permeability and retention (EPR) effect, is the rational 
basis for passive targeting in antitumor drug delivery 
[1, 7, 89]. However, proliferating tumor cells compress 
the intratumor blood and lymphatic vessels, leading 
to a uniformly elevated interstitial fluid pressure. 
Additionally, increased fibrillar collagens (such as 
type I and type III) in some tumor interstitial matrix 
can greatly hinder larger (>60 nm) nanocarriers from 
penetrating deeply into the tumor parenchyma [19, 
90, 91]. Therefore, pH-responsive nanocarriers with 
programmable size changes can be automatically 
altered during each stage of the anti-tumor drug 
delivery. 
Recently, remarkable advances in 
size-dependent smart nanocarriers have attracted 
great interest for their advanced and efficient 
antitumor drug delivery as well as their reduced 
systematic side effects. Although pH-responsive [6, 
92-102] and size-related [1, 20, 83, 103, 104] antitumor 
studies have been amply discussed in previous 
review articles, there is a need to review several 
aspects of endogenous pH-responsive nanocarriers 
for antitumor therapy. Considering the unique 
advantages of nanocarriers’ size characteristics for 
antitumor drug delivery, this review focuses on 
pH-responsive nanocarriers with programmable size 
changes in antitumor applications, especially 
highlighting recently advanced design strategies. 
2. Endogenous pH-responsive carriers 
with programmable size changes for 
antitumor drug delivery 
To achieve efficient targeted payload delivery, 
nanocarriers must meet the following challenges: (a) 
long-term stability in blood circulation as well as 
retention within tumor lesions, (b) ability to 
accumulate at tumor tissue site and penetrate deeply 
into tumor parenchyma, and (c) avoiding the 
premature release of payload before reaching the 
target and then accelerating drug release once at the 





target [105]. To achieve safe and efficient antitumor 
drug delivery, pH-responsive nanocarriers with 
programmable size changes based on the 
tumoral/intracellular phase-transition (protonation/ 
deprotonation and cleavable bond) (Table 1) offer a 
feasible approach for overcoming many contradictory 
requirements during various phases.  
2.1. pH-responsive aggregation for tumor 
retention 
2.1.1. Design principle 
The long-term stability in the circulatory system 
necessitates nanocarriers with a different size than 
that required for uptake by tumor cells [8, 76, 90, 
177-179]. From previous anti-tumor studies, the 
well-accepted size for long-term blood circulation is 
around 100 nm due to the size-dependent balance 
between organ filtration and tumor vessel 
extravasation [8, 76, 83]. After intravenous injection, 
carriers circulating for a longer time in the blood have 
a better chance of accumulating in the tumor tissue via 
EPR effects.  
Therefore, for prolonging the blood circulation 
time, it is extremely important to avoid nonspecific 
interactions with blood components and other 
off-targeted cells. Also, nanocarriers undergo a series 
of screening events by the reticuloendothelial system 
(RES) and organs such as the liver, spleen, lung, and 
kidney. Improvement of their “stealth” capabilities is 
a key aspect for prolonging blood circulation time. 
Furthermore, once accumulation begins in tumor 





Figure 1. Illustration of size-dependent antitumor drug delivery. stage 1: extravasation based on the tumor vascular pore size selection (Three arrows indicate that 
less phagocytosis by MPS, longer circulation time in bloodstream, and higher extraversion at tumor vasculature are beneficial for enhancing passive targeting of tumor 
by EPR effect); stage 2: antitumor drug delivery in the highly permeable tumor tissue; stage 3: antitumor drug delivery in the poorly permeable tumor tissue; stage 4: 
tumor cell uptake and subsequent intracellular drug release. pH ~7.4 for normal tumor tissue and blood stream, ~6.5 for tumor tissue, ~5.5 for endosome, ~5.0 for 
lysosome. 





Table 1. The typical representative pH-responsive structures in the tumoral and intracellular endo/lysosomes. 
 Phase-transition Structure (Name) pH Examples 












~ 7.0 [109-112] 
 
(PSD) 
~ 7.0 [113-115] 
 
(PHis) 








~ 6.8 [53, 60, 124, 125] 
 
(Benzoic-imine) 







~ 6.3 [49, 52, 64, 77, 130] 
 
(P4VP) 
~ 5.6 [131-134] 











~ 6.3 [138-141] 
 
(PEAA) 
~ 5.6 [142, 143] 
 
(PAsp) 




~ 5.5 [55, 148-150] 
 
(Hydrazone) 
~ 6.0 [117, 151-153] 
 
(Imine) 
~ 6.5 [154-157] 
 
(β-Thiopropionate) 
~ 5.5 [158-161] 
 
(Ketal) 
~ 5.0 [162-165] 
 
(Acetal) 
~ 5.0 [166-169] 
 
(Cyclic acetal) 
~ 5.0 [170-172] 
 
(Ortho ester) 
~ 5.0 [72, 173-176] 







Figure 2. (A) Schematic illustration of pH-responsive aggregation of gold nanoparticlesenhancing targeted retention and cellular uptake in response to the tumor 
extracellular acidic stimuli. (B) Illustration of the size-dependent prolonging of blood circulation time and targeted tumor retention. (C) TEM images of 
pH-responsive aggregation. Reproduced with permission from [89], copyright 2013 American Chemical Society. 
 
As a result of the time- and 
concentration-dependent internalization process 
caused by enhanced interactions between 
nanocarriers and cells, carriers can have increased 
chances of tumor cells uptake and retention in tumor 
tissue [1, 89, 180]. Cytotoxicity of aggregated 
nanocarriers compared to non-aggregated ones has 
also been reported [179]. All in all, nanocarriers must 
be “stealthy” in blood circulation to evade 
undesirable RES recognition or protein/cell adhesion 
but must be “sticky” to interact with tumor cells. To 
this end, nanoparticles with sizes of 20-200 nm are 
appropriate to avoid undesirable clearance through 
the nonspecific adsorption and urinary excretion. 
However, the design strategy employed may need to 
take into account the opposing requirements 
depending on the intercellular space. For the highly 
permeable tumor parenchyma with large intercellular 
space, the aggregated nanoparticles can be retained in 
the tumor tissue to enhance tumor cell endocytosis. 
This is one of the areas where the tunable properties 
of nanocarriers are advantageous as their surfaces can 
be functionalized appropriately to fulfill size 
requirement. 
2.1.2. pH-responsive aggregation based on 
protonation/deprotonation 
pH-responsive aggregation triggered by slightly 
acidic stimuli of the extracellular tumor matrix is a 
suitable mechanism for designing nanocarriers with 
low uptake by normal cells but high uptake by tumor 
cells. Based on the protonation/deprotonation 
transition triggered by mild acidic stimuli, Ji and 
coworkers prepared a series of mixed-charge 
zwitterionic monolayer-modified gold nanoparticles 
(Figure 2) [89, 181]. Owing to zwitterionic monolayer 
protonation/deprotonation balance, the optimized 
nanoparticles were stable at the physiological pH of 
the bloodstream and normal tissues but rapidly 
aggregated within a few seconds in response to a 
slight pH change from 7.4 to 6.5. This work 
demonstrated that controllable aggregation at tumor 
sites could enhance retention efficiency and cellular 
uptake of nanoparticles in tumors for photo-thermal 
tumor-targeted diagnosis and therapy. Inspired by 
this study on the surface charge conversion resulting 
from ultra acid-labile amide bond breakage, we 
fabricated a pH-responsive polymeric nanocarrier 
with tumor-targeted aggregation properties for 
enhanced retention and endocytosis (Figure 3) [52]. 
The doxorubicin-loaded smart nanocarrier was 
constructed from succinic anhydride-modified poly 
(2-diisopropylaminoethyl methacrylate)-block-poly 
(2-aminoethyl methacrylate hydrochloride) (PDPA-b- 
PAMA/SA@DOX) and was responsive to a slightly 
acidic stimulus. It exhibited size aggregation from 
~154 nm to ~1517 nm due to the pH-responsive 
protonation of PDPA block-induced electrostatic 
attraction with its negatively charged corona. 
Importantly, cell uptake studies showed that the 
aggregated nanomedicine was endocytosed by tumor 
cells at pH 6.5 rather than pH 7. 4. Using the same 





mechanism of pH-sensitive surface charge transition, 
Chiu and coworkers constructed a nanocarrier using 
N-acetyl histidine-modified D-α-tocopheryl poly-
ethylene glycol succinate on the surface of poly 
(lactic-co-glycolic acid) [182]. The increased 
protonation of imidazole groups from histidine 
residues resulted in the lack of sufficient interparticle 
electrostatic repulsion for maintaining stable 
individual particles at pH 6.5, and the DOX-loaded 
nanoparticles with an almost neutral surface charge 
aggregated into large clusters. Both in vitro and in vivo 
results confirmed that tumor acidity-triggered surface 
charge neutralization and aggregation could 
significantly enhance tumor cell uptake. Ji’s group 
also reported a pH-responsive supra-molecular 
prodrug micelle based on the host-guest inclusion 
[183]. The size of this supra-assembly could be tuned 
by pH changes showing significant aggregation 
triggered by slight acidity of the tumor extracellular 
matrix. Benefitting from aggregation-induced 
accumulation in tumor tissues, this supra-assembly 
exhibited desirable antitumor effect by efficiently 
inhibiting tumor proliferation. In these design 
strategies, the pH-responsive size aggregation based 
on the protonation/deprotonation is reversible, so the 
nanoparticles can disperse as single nanoparticle once 
the pH condition recovers, which is convenient for its 
preparation, storage, and further functionalization. 
2.1.3. pH-responsive aggregation based on cleavable 
bond at acidic pH 
Recently, a nanocarrier with programmable size 
changes was designed to satisfy the different phases 
of the drug delivery process by Chen’s groups [184]. 
An ideal smart polymeric gene complex was prepared 
from pH-responsive cleavable polyethylene glycol 
(PEG) bonded in situ on the surface of a primary 
complex of polyethyleneimine (PEI), poly-L- 
glutamate and therapeutic genes via the Schiff base 
reaction (Figure 4). At the physiological pH 7. 4, the 
PEG cross-linked complex could shield the surface 
positive charges and enhance its stability to reduce 
side effects, prevent premature gene release, and 
prolong blood circulation time. However, once the 
complexes accumulated in tumor tissues by EPR, the 
ultra pH-sensitive Schiff base bonds were responsive 
to the slightly acidic environment of tumor tissue. The 
PEG surface layer rapidly detached from the complex. 
The complex without PEG corona exhibited a higher 
positive charge potential and larger size facilitating 
tumor cellular uptake and enhancing antitumor gene 
delivery. In this design, the cross-linking PEG corona 
could shield the surface positive charge and compress 
the nanoparticles tightly, exhibiting prolonged blood 
circulation, enhanced stability, and reduced 
cytotoxicity. The PEG layer could be rapidly detached 
by the acid labile cleavable bond in response to the 
slight acidity of the tumor tissue exposing the surface 
positive charge and inflated size to promote tumor 
cell endocytosis. However, compared to the 
protonation/deprotonation transition, pH-responsive 
size change induced by the acid labile cleavable bond 
is generally irreversible. Therefore, the acid labile 
nanoparticles have a potential risk of instability in 
their preparation, storage, and application. 
 
2.2. pH-responsive size shrinkage for deep 
tumor penetration 
2.2.1. Design principle 
The size of nanocarriers is a significant factor in 
promoting their accumulation and penetration in 
tumor tissues [1, 76, 185]. To sufficiently illustrate the 
important role of size in drug delivery, Tang et al. 
have fabricated micelles of the same chemical 
structures and physical properties from a single 
copolymer but ranging in size from 20 nm to 300 nm. 
Their results indicated that the optimal size of 
nanocarriers through the cascade processes was 
different at different stages, i.e. the optimal size range 
for suitable blood circulation time and tumor 
accumulation was between 100 and 160 nm. However, 
greater accumulation of the large micelles (100 nm) at 
tumor sites did not result in significantly improved 
therapeutic efficacy because of their poor tumor 
penetration compared to that of the smaller micelles 
(30 nm). A relatively large size (100 nm) is needed for 
accumulation at tumor sites and a smaller size 
(preferably <20 nm) is required for tumor penetration. 
Therefore, the two most commonly-used strategies 
are to construct slightly acidic pH-responsive 
nanocarriers with large aggregation for accumulation 
at the tumor site [52, 89, 186] or with a small size for 
deep-seated tumor penetration [25, 90, 187]. In 
contrast to the pH-responsive aggregation in the 
highly permeable tumor parenchyma, the poorly 
permeable tumor parenchyma exhibits narrow 
intercellular spaces resulting from the increased 
fibrillar collagen crosslinking. For this reason, 
developing the ultra-pH-responsive nanoparticles 
with size shrinkage in response to mild acidic 
stimulus is beneficial for deep penetration into the 
tumor parenchyma to inhibit tumor proliferation.  






Figure 3. (A) Scheme and (B) Digital image of the tumor-targeted aggregation of pH-responsive polymeric nanomicelles for enhanced retention at tumor tissue and 




Figure 4. (A) Schematic of the ultrasensitive pH-triggered charge/size dual-rebound gene delivery system for efficient antitumor applications. (B) Fast hydrodynamic 
charge/size dual-rebound property and (C) TEM of the gene delivery system. (GP)D and P[(GP)D] represent (PLG/PEI)/DNA and PEG[(PLG/PEI)/DNA], respectively. 
Reproduced with permission from [184], copyright 2016 American Chemical Society. 






Figure 5. Schematic illustration of a multistage pH-responsive stepwise size reduction and charge-reversal polymeric nanocarrier. (A) negatively charged nanocarrier 
at neutral pH to enhance blood retention, (B) passive accumulation of larger size nanocarriers in the tumor via EPR effect, (C) the first-stage size reduction into 
smaller linear copolymers for tumor tissue deep penetration, (D) increased nanocarrier uptake by tumor cells mediated by concomitant R8NLS, (E) the second-stage 
size reduction into therapeutic drug for intracellular release in the endo/lysosomal compartment, (F) endo/lysosome escape and nuclear targeted delivery. 
Reproduced with permission from [189], copyright 2015 Wiley-VCH. 
 
2.2.2. pH-responsive size shrinkage based on cleavable 
bond at tumor extracellular acidity for tumor 
parenchyma penetration 
The pH-responsive size shrinkage due to the 
acidic environment of the extracellular tumor matrix 
provides a feasible strategy to facilitate deep 
penetration of nanocarriers into the tumor’s dense 
collagen parenchyma. Thayumanavan and coworkers 
constructed a series of ultra pH-sensitive 
size-changeable nanogel clusters [42]. Large 
nanoclusters were obtained by using a pH-sensitive 
dynamic covalent imine bond to cross-link individual 
nanogels. Under physiological pH conditions, 
nanoclusters showed a relatively large size and less 
positive surface charge to prolong the blood 
circulation time. Because of the breakage of 
cross-linked dynamic imine bonds triggered by the 
tumor-acidity at pH 6.5, nanoclusters transformed 
into the original nanogel, exhibiting small size and a 
more positive surface charge to promote deeper 
penetration into the tumor matrix. Wang’s group 
reported pH-responsive clustered nanoparticles, 
comprising the platinum-poly(amidoamine) den-
drimer prodrug-conjugated at the terminal of the 
amphiphilic poly(ethylene glycol)-b-poly(Ɛ-caprol-
actone) block polymer using the acid-labile bond [187]. 
These smart clustered nanoparticles showed an initial 
diameter of ~100 nm, and discharged the small size 
(~5 nm) prodrug by cleaving its conjugation in the 
acidic environment within the tumor for deep 
penetration and enhanced endocytosis, followed by 
further intracellular reduction to kill tumor cells. Ge’s 
group reported a supramolecular polymeric nanogel 
based on the host-guest interaction between 
adamantanine and β-cyclodextrin moieties [188]. Due 
to the cleavage of the benzoic imine linkage in 
tumor-acidic conditions, this nanogel could 
reorganize into smaller nanoparticles from ~220 nm to 
~25 nm. For targeted drug delivery into the tumor cell 
nucleus, Huang and colleagues synthesized a 
multistage nanovehicle with pH-responsive stepwise 
size reduction and charge reversal using an ultra 
pH-sensitive charge-reversal 2,3-dimethylmaleic 
amine modification and hydrazone linkage (Figure 5) 
[189]. The neutrally charged nanovehicle with 
relatively large size (~55 nm) showed good blood 
persistence and excellent accumulation in tumor sites 
at pH 7.4. Responding to the acidic stimulus of tumor 
tissue, the nucleus-homing cell-penetrating 
peptide-modified drug conjugate was separated from 
the disassembled large nanovehicle, and had a size of 
~10 nm in diameter, which allowed deeper tumor 
matrix penetration and better cellular internalization. 
Subsequently, the antitumor drug was cleaved from 
the conjugate in the acidic microenvironment of the 
endosome, and efficiently entered the nucleus via 
nuclear location signaling. Benefitting from the 





stepwise size reduction and on-demand target moiety 
exposure, this multistage nanovehicle greatly 
improved the antitumor drug efficiency inhibiting 
HeLa tumor growth in nude mice by 75%. 
2.2.3. pH-responsive size shrinkage based on 
protonation at tumor extracellular acidity for tumor 
parenchyma penetration 
Another study by Ge and co-workers used ultra 
pH-sensitive charge reversal micelles with a large size 
(114 nm at pH 7.4) to introduce pH-responsive 
hydrophobicity to hydrophilicity transition of tertiary 
amine. Under slightly acidic condition (pH 6.8), this 
specifically accelerated the release of an encapsulated 
smaller poly(amidoamine) dendrimer-conjugated 
prodrug (several nanometers) for deep tumor 
penetration, and subsequently released the active 
drug by cleaving the conjugate in the intracellular 
reduction environment [190]. Recently, Wang and 
colleagues have developed a class of pH-responsive 
nanoparticles superstructures with ultrasensitive size 
shrinkage for improving deep tumor penetration and 
efficient antitumor drug delivery (Figure 6) [90]. Due 
to the rapid pH-responsive protonation of the 
ionizable tertiary amine group, this smart 
superstructure had an initial size of ~80 nm at the 
physiological pH of 7.4 during its circulation in the 
blood, but undergoes a dramatic and sharp size 
reduction to less than 10 nm in the slightly acidic 
microenvironment of the tumor. The ultra 
pH-sensitive size-changeable superstructures did not 
only facilitate enhanced targeted tumor accumulation 
by EPR by utilizing the long-circulation benefit of 
large nanoparticles but also promoted deeper tumor 
penetration by taking advantage of the increased 
penetration capability of smaller nanoparticles, which 
ultimately improved efficiency of antitumor therapy 






Figure 6. (A) Structure of polymer-drug conjugate. (B) Schematic illustration of the pH-sensitive cluster nanobomb at neutral pH and the disintegration into small 
particles at tumor due to its acidic pH. (C) Schematic illustration of cluster nanobomb for in vivo drug delivery in the poorly permeable pancreatic tumor model. (I) 
large superstructure for prolonged blood circulation, (II) targeted tumor accumulation via EPR, (III) pH-responsive disintegration into small particles for deep tumor 
parenchyma penetration. Hydrodynamic diameter and TEM of polymer-drug conjugate at (D) pH 7.4 and (E) pH 6.7. (F) pH-dependent size change detected by DLS. 
Reproduced with permission from [90]. Copyright 2016, American Chemical Society. 






Figure 7. pH-responsive size-shifting cross-linked micelle nanoclusters for enhanced tumor targeting and deep penetration. Reproduced with permission from [91], 
copyright 2016 American Chemical Society. 
 
2.2.4. pH-responsive size shrinkage based on cleavable 
bond at tumor intracellular acidity for endo/lysosome 
escape 
pH-responsive size shrinkage triggered by acidic 
stimuli of endo/lysosomes is helpful for facilitating 
the escape of nanocarriers from these subcellular 
compartments. Sha and colleagues prepared a 
size-shifting micelle nanocluster based on a 
cross-linked framework interspersed with small 
micelles using the emulsion-evaporation method 
(Figure 7) [91]. The cross-linked nanocluster was 
stable with a size of around 104 nm and prolonged 
half-life for increased tumor accumulation by EPR. 
Due to the proton sponge effects of polyetherimide in 
an acidic environment, the cross-linked framework of 
nanoclusters was able to swell and disintegrate, thus 
accelerating the release of individual micelles (14 nm) 
and penetration into the cytoplasm. To ensure 
delivery of antitumor drug into the nucleus, Chen and 
coworkers designed a large compound nanoparticle 
with pH-activated size reduction for in vivo 
nucleus-targeted gene delivery (Figure 8) [191]. This 
large compound nanoparticle with detachable PEG 
shell and folate decoration had a size of ~150 nm 
under neutral conditions. Once internalized by tumor 
cells, breakage of the benzoic imine bond of PEG 
conjugate in response to lower pH led to dissociation 
of the PEG shell resulting in the formation of smaller 
entities (~40 nm) exposing a previously shielded 
nuclear localization signal oligo-L-lysine. The 
resultant smaller nanoparticles could enter into the 
nucleus via the nucleopores, causing a 20-fold higher 
cytotoxicity in vitro and greater tumor suppression in 
animal models compared with the native drug. For 
endo/lysosome escape and nuclear entry, the size 
shrinkage in intracellular acidic conditions could 
greatly improve the therapeutic efficacy due to the 
reduced drug loss. 
 
Figure 8. Illustration of the large compound nanoparticles with pH-activated 
size reduction property for in vivo nucleus-targeted gene delivery. 






Figure 9. Illustration of DOX-loaded micelles for rapid intracellular drug release in response to the acidic stimulus of endo/lysosome in anti-cancer therapy. 
Reproduced with permission from [64], copyright 2014 Royal Society of Chemistry. 
 
2.3. pH-responsive swell or disassembly for 
burst drug release 
2.3.1. Design principle 
pH-responsive size change nanocarriers can also 
be constructed for encapsulated drug release 
intracellularly. After being endocytosed by tumor 
cells, the instantaneous pH-responsive swell 
accelerates release of encapsulated drugs from the 
loose nanocarriers and the pH-responsive 
disassembly results in the burst drug release [30, 49, 
64, 77, 192]. The controllable pH-responsive drug 
release determines the therapeutic efficacy and side 
effects of the drug [193-195]. The ideal nanocarrier 
must tightly retain the encapsulated drug without 
premature release during transport but must show 
burst release once inside tumor cells to overcome 
multidrug resistance and subsequently efficiently 
induce tumor cells apoptosis [70, 105, 196-200]. 
However, nanocarriers do not conform to the ideal 
drug release profile; there is burst release of up to 30% 
during the first several hours and sustained slow drug 
release over the following several days [196]. The lost 
drug not only leads to reduced therapeutic efficiency 
but also increases toxicity to healthy cells and organs. 
Therefore, improvements in release kinetics are still a 
tremendous challenge. To match drug release as close 
to the ideal profile as possible, the tight encapsulation 
of the drug in the nanoparticles is required and their 
rapid disassembly to accelerate the release of the 
payload drug in response to the intracellular acidic 
environment. Many mechanisms including 
appropriate cross-linking, reversible conjugation, or 
specific physicochemical property transformations 
based on the pH are adapted for a viable strategy to 
modulate release kinetics and reaching an appropriate 
therapeutic window. The payload drug would be 
ineffective below a certain concentration [119, 
201-204]. 
2.3.2. pH-responsive swell or disassembly based on 
protonation  
pH-responsive protonation resulting in 
polymeric hydrophobic-hydrophilic conversion in the 
acidic microenvironment of endo/lysosomes is one of 
the most utilized strategies for controlling the size of 
nanocarriers. For example, we previously prepared a 
series of amphiphilic block copolymers based on the 
pH-sensitive block poly[2-(diisopropylamino)ethyl 
methacrylate] (pKa ∼6.2) [64, 77, 124]. The 
pH-sensitive block copolymers could self-assemble 
into nano-micelles with a hydrophobic PDPA core for 
tightly encapsulating DOX during circulation and 
then rapidly released DOX intracellularly once 
transformed from amphiphilicity to double 
hydrophilicity due to protonation of PDPA block in 
the acidic environment of tumor cells (Figure 9) [64]. 
Dong and colleagues prepared integrin-targeted 
zwitterionic polymeric nanoparticles based on the 
ultra pH-sensitive PDPA [205]. In their study, 24% of 
the loaded drugs was released at pH 7.4 within 36 h, 
but the released drugs increased to 60% at pH 6.0 
within 24 h and eventually 100% at pH 5.0 within 5 h. 
Shuai’s group developed a highly packed 





interlayer-crosslinked nano-micelles for reduction- 
and pH-responsive burst drug release (Figure 10) 
[196]. Benefitting from the hydrophobicity of the 
2-(diisopropylamino) ethyl amine groups in 
copolymer at pH 7.4 and disulfide functional 
cross-linkage in a normal reduction environment, 
these micelles were capable of tightly encapsulating 
DOX to avoid drug leakage during storage and blood 
circulation. The pH-responsive hydrophilicity 
conversion and reduction-responsive cross-linker 
breakage in the lysosomes then led to the disassembly 
of nano-micelles into separate copolymers; 
Subsequently, there was a burst drug release (more 
than 95% of loaded DOX released in a 
lysosome-simulated aqueous solution of 10 mM 
dithiothreitol at pH 5.0) to induce cell apoptosis. 
 
 
Figure 10. Highly packed interlayer-crosslinked nanomicelles for reduction- 
and pH-responsive collectively triggered burst drug release. Reproduced with 
permission from [196], copyright 2011 Wiley-VCH. 
2.3.3. pH-responsive swell or disassembly based on 
acid-labile cleavable bond  
Another pH-responsive intracellular release 
strategy is to use acid-labile bond cleavage. 
pH-responsive disassembled nanocarriers based on 
charge-reversal or degradation mechanisms are 
feasible for obtaining a burst release profile. Zhong’s 
group improved a number of pH-responsive 
degradable polymeric nanocarriers using acid-labile 
polycarbonate modified for intracellular drug 
delivery (Figure 11) [3, 206-212]. The polycarbonate 
modification provided the amphiphilic feature for a 
remarkably high drug loading content. Notably, these 
nanocarriers are stable at pH 7.4 but swell and 
eventually disassemble for fast hydrolysis of the 
polycarbonate in the acidic conditions of 
endo/lysosomes.  
Given the high drug-carrying capacity and 
tunable drug-release kinetics, the pH-responsive 
prodrug conjugates provide a platform for further 
increasing drug delivery efficiency [69, 70, 213, 214]. 
Zhong and coworkers developed a pH-sensitive 
nano-micelle based on the acid-labile acetal bridging 
polymer and drug conjugates for accelerated 
intracellular antitumor drug release [215]. In release 
studies performed in vitro, the acetal-link breakage 
resulted in paclitaxel (PTX) monomer recovery and 
swelling of prodrug nanoparticles, showing that PTX 
release was highly pH-dependent, i.e. 86.9%, 66.4% 
and 29.0% in 48 h at pH 5.0, 6.0, and pH 7.4, 
respectively. Wang and colleagues developed a dual 
tailor-made pH-responsive polymer-drug conjugate 
to inhibit drug-resistant cancer stem cells (Figure 12) 
[53]. This advanced polymeric prodrug could respond 




Figure 11. Acid-labile polycarbonate-modified pH-responsive degradable polymeric nanocarriers showing swelling and eventual disassembly for controlling 
intracellular drug release. 





through chemically defined mechanisms. It was 
expected to have a prolonged blood circulation, 
accumulation in the tumor via EPR, and endocytosis 
through pH-responsive surface charge conversion 
from negative to positive in response to the mild acid 
conditions in tumor tissue. Interestingly, nanosized 
prodrug rapidly disassembled into the drug monomer 
due to the acid-labile hydrazone bond cleavage in 
endo/lysosomes. This multifunctional nanosized 
prodrug greatly enhanced antitumor efficacy 
providing an advanced guide for antitumor drug 
delivery research and clinical applications.  
Gu et al. improved a potential theranostic 
reagent using a transformable liquid-metal 
nanomedicine with a polymeric shell for 
encapsulating DOX and a liquid inorganic core for 
fusion and subsequent degradation in a mildly acidic 
environment (Figure 13) [216]. Within 4 h, the 
cumulative amount of drug released in the acidic 
buffer of pH 5.0 was significantly higher than that in 
the neutral condition of pH 7.4 (> 50% for DOX and 
44% for paclitaxel). The increased drug release at pH 
5.0 resulted from the liquid-metal core fusion 
mediating the disruption of the polymeric shell and 
subsequent dissociation of the drug-loaded surface 
ligand. Besides, this liquid-metal nanoformulation 
exhibited a contrast-enhancing capability for imaging 
applications, and eventually degraded under mildly 
acidic condition showing excellent biocompatibility. 
3. Advanced endogenous pH-responsive 
carriers with programmable size changes 
for tumor imaging 
Besides being useful for antitumor therapy, the 
pH-responsive size-changeable design strategy has 
also been exploited for tumor diagnosis [217-219]. For 
example, to overcome the low optical absorbance in 
biological tissues’ near-infrared optical window, 
Chang et al. developed novel melanin-like 
nanoparticles by modifying the hydrolysis- 
susceptible surface citraconic amide for photoacoustic 
imaging (Figure 14) [55]. These improved 
nanoparticles were able to aggregate within a mildly 
acidic environment, and, due to their overlapping 
thermal fields, resulted in the photoacoustic signal 
strength amplification (8.1 times at pH 6.0 than that at 
 
Figure 12. (A) Illustration of the dual tailor-made pH-responsive polymer-drug conjugate to inhibit drug-resistant cancer stem cells. (B) Acid-labile breakage of the 
polymer-drug conjugate. (C) In vitro pH-sensitive drug release profiles. Reproduced with permission from [53], copyright 2011 American Chemical Society. 
 





pH 7.4) in the near-infrared window of biological 
tissues without absorption tuning. The unique 
characteristic of photoacoustic amplification in 
melanin-like nanoparticle clusters might allow their 
use as a contrast agent for highly sensitive in vivo 
tumor target imaging. This innovative targeted tumor 
imaging based on the pH-responsiveness unveiled 
great opportunities for many basic research studies 
and clinical explorations. Recently, Gao and 
colleagues have fabricated a large number of the 
ultra-pH-responsive nanosensors for amplifying 
signals based on the positive cooperativity of the 
noncovalent selfassembly of the fluorescence-labeled 
functional block copolymers [66, 67, 71, 106-108, 114, 
220-226]. Typically, a hybrid nanotransistor probe, 
composed of a molecular mixture of three different 
ultra-pH-responsive block copolymers, served as a 
binary pH threshold sensor exhibiting dramatic signal 
amplification (>30-fold) and sharp (<0.25 pH) acidic 
response capabilities [220]. The hybrid nanotransistor 
stayed “OFF” at pH 7.4, resulting from the dramatic 
fluorescence quenching through the 
hetero-/homo-molecular fluorescence energy transfer 
in micelle state. After endocytosis, the 
ultra-pH-responsive block copolymer components 
disassembled and fluoresced sequentially as the pH 
value decreased. After each pH transition encoding 
with a unique fluorescent reporter, the acidification 
kinetics at single-organelle resolution could be 
quantified using digitization paradigm by a series of 
barcodes with binary (0 and 1) output in each channel 
reporting the luminal pH of the individual endocytic 
organelle (Figure 15). This novel nanoprobe provided 
a feasible platform for imaging and new biological 
investigations in tumor pathology. The preliminary 
exploration of the pH-responsive size changeable 
nanoprobes showed exciting perspectives in tumor 
imaging diagnosis. For the same design mechanism, 
the pH-responsive nanoparticles with programmable 
size changes provided a feasible platform to integrate 





Figure 13. Illustration of the transformable liquid-metal nanomedicine for the antitumor application. (A) Preparation and (B) Main components of liquid-metal 
nanomedicine. (C) pH-responsive delivery of the DOX-loaded liquid-metal nanomedicine for targeted antitumor therapy. (D) Acid-triggered fusion and degradation 
process of liquid-metal nanomedicine. (E) Chemical structures of the main components. Reproduced with permission from [216], copyright 2015 Nature Publishing 
Group. 






Figure 14. (A) Schematic illustration of pH-responsive aggregation-induced amplification of the photoacoustic signal from Melanin-like nanoparticles and (B) Surface 
modification of the bare Melanin-like nanoparticles and their aggregation under mildly acidic condition. Reproduced with permission from [55], copyright 2016 Royal 
Society of Chemistry. 
 
 
Figure 15. (A) Schematic of the ultra-pH-responsive hybrid nanotransistor to digitize organelle pH after receptor-mediated endocytosis in tumor cells. (B) The 
count rates and normalized fluorescence intensity of the hybrid nanotransistor are plotted at different pH values. (C) Representative fluorescence images of 
multispectral ultra-pH-responsive hybrid nanotransistor at different pH values. Yellow is the merged color of green and red signals. White is the merged color of blue, 
green, and red signals. Reproduced with permission from [220], copyright 2017 Wiley-VCH. 
 
4. Conclusions and perspectives 
pH-responsive nanocarriers with programmable 
size changes have proven to be a powerful and 
flexible platform for designing more effective 
anticancer drug delivery systems with higher 
therapeutic efficacy and fewer clinical side effects. In 
this review, we focused on various advanced 
pH-responsive size-changeable design strategies: (a) 
Nanocarriers with appropriate size are necessary for 
avoiding undesirable clearance during circulation by 
nonspecific MPS and for enhancing accumulation and 
retention at tumor sites via the EPR effect. (b) For 
highly permeable tumors (such as C26 colon tumor), 
the slightly acidic environment in tumor tissues can 
promote uptake of nanocarriers with pH-responsive 
aggregation through concentration- and 
time-dependent interaction effects. (c) For poorly 
permeable tumors (such as the BXPC-3 pancreatic 
tumor), nanocarriers with pH-responsive size 
shrinkage are capable of accelerating nanocarrier 
penetration into the tumor parenchyma, escaping 
from endo/lysosomes, and delivering the drug into 
the nucleus. (d) After internalization by tumor cells, 
nanocarriers with pH-responsive swell and even 
disassembly can accelerate drug release to provide the 





required therapeutic dose for inducing tumor cell 
apoptosis. (e) pH-responsive nanoprobes with 
programmable size changes are expected to be useful 
for tumor imaging diagnosis.  
Although considerable progress has been made 
with pH-responsive nanocarriers with programmable 
size changes, some challenges still exist. For example, 
rapid mutations of malignant tumors may result in 
unpredictable and unstable pathological environment 
including extracellular pH gradients, varying tumor 
vascular leakage by changing pore diameter, and 
tumor parenchyma collagen density. The 
synchronous development of real-time technology in 
tumor imaging and diagnosis is needed to detect the 
precise pathological changes for designing an 
accurate and targeted clinical approach. Furthermore, 
the strategy in the selection of sizes for nanocarrier 
aggregation or deep tumor penetration should be 
designed based on the permeability of various tumor 
types and location. For example, different size 
nanocarriers (with diameters of 30, 50, 70 and 100 nm) 
exhibit efficient penetration into the highly permeable 
tumor, but only small-sized nanocarriers with a 
diameter of 30 nm can penetrate the poorly permeable 
pancreatic tumors [227]. For tumors with low blood 
supply and mesenchyme-enriched tumors, the size 
reduction strategy for deep tumor penetration is a 
better choice for enhancing antitumor therapeutic 
efficacy. On the other hand, the excessive pursuit of 
stimuli-responsiveness may come at the cost of loss of 
stability which may cause serious physiological 
toxicity. Therefore, it is necessary to achieve a rational 
balance between ultra sensitivity and stability. 
Although pH-responsive size variation is a major 
aspect of designing nanocarriers, it is not the only 
criterion that is worthy of consideration. Sophisticated 
novel antitumor nanocarriers must navigate a hostile 
and complex environment in vivo and, therefore, a 
variety of mechanisms are needed to integrate 
multiple stimuli (temperature, redox, enzyme, 
glucose, ion, etc.) as well as different factors (surface 
charged potential, hydrophilic-hydrophobic balance, 
shape etc.). Also, improving biocompatibility and 
degradability as well as functionality is important for 
the successful implementation of clinical 
nanomedicine. In summary, pH-responsive 
nanocarriers with programmable size changes 
provide an excellent platform for precise and 
personalized treatment for current antitumor therapy. 
However, a great number of challenges remain for the 
future clinical nanomedicine. 
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